$5.41 Billion is the total value of Avoro Capital Advisors LLC's 39 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 30.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UTHR | Sell | UNITED THERAPEUTICS CORP | $612,751,000 | -12.4% | 2,926,500 | -1.5% | 11.32% | -18.1% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $350,965,000 | +38.1% | 3,175,000 | -6.3% | 6.48% | +29.1% |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $221,177,000 | +11.5% | 1,105,000 | -18.8% | 4.09% | +4.2% |
| ISEE | Sell | IVERIC BIO INC | $105,846,000 | +54.5% | 5,900,000 | -17.1% | 1.96% | +44.5% |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $86,412,000 | -15.1% | 9,020,000 | -2.2% | 1.60% | -20.6% |
| KURA | Sell | KURA ONCOLOGY INC | $48,152,000 | -45.3% | 3,525,000 | -26.6% | 0.89% | -48.8% |
| PMVP | Sell | PMV PHARMACEUTICALS INC | $36,414,000 | -17.6% | 3,060,000 | -1.3% | 0.67% | -22.9% |
| GNCA | Exit | GENOCEA BIOSCIENCES INC | $0 | – | -5,084,184 | -100.0% | -0.00% | – |
| AMTI | Exit | APPLIED MOLECULAR TRANS INC | $0 | – | -1,030,000 | -100.0% | -0.06% | – |
| XBI | Exit | SPDR SERIES TRUST - S&P BIOTECHetf | $0 | – | -900,000 | -100.0% | -1.32% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.